Daily Ards Research Analysis
Today's ARDS-related research highlights a preclinical repurposing study showing cilostazol mitigates LPS-induced acute lung injury in rats. The drug attenuated inflammatory signaling (NF-κB/TLR4/JAK-STAT3), reduced edema and cytokines, and improved respiratory parameters, supported by in silico multi-target docking.
Summary
Today's ARDS-related research highlights a preclinical repurposing study showing cilostazol mitigates LPS-induced acute lung injury in rats. The drug attenuated inflammatory signaling (NF-κB/TLR4/JAK-STAT3), reduced edema and cytokines, and improved respiratory parameters, supported by in silico multi-target docking.
Research Themes
- Drug repurposing for ALI/ARDS
- Inflammatory signaling modulation (NF-κB/TLR4/JAK-STAT3)
- Integrative in silico docking with in vivo validation
Selected Articles
1. Investigation of the protective effect of cilostazol on acute lung injury-mediated inflammation and in silico molecular modelling studies of inflammatory signalling pathway: a repurposing study.
In an LPS-induced rat ALI model, cilostazol bound multiple inflammatory proteins in silico and reduced oxidative stress, cytokines (IL-6, TNF-α), KL-6, LDH, MPO, CRP, NO, edema, vascular leakage, and inflammatory cell recruitment in vivo. It downregulated TNF-α, NF-κB, TLR4, and JAK/STAT3 mRNA and improved total lung capacity, supporting repurposing for ALI/ARDS.
Impact: This study identifies multi-target anti-inflammatory actions of cilostazol and demonstrates preclinical efficacy in ALI, suggesting a plausible therapeutic strategy for ARDS. The integrative in silico–in vivo approach provides mechanistic insight for repurposing.
Clinical Implications: Although preclinical, findings justify exploration of cilostazol as an adjunctive anti-inflammatory therapy for ALI/ARDS, with careful attention to bleeding risk and dosing. Clinical trials are needed to assess efficacy, safety, and patient selection.
Key Findings
- In silico docking predicted cilostazol binding to 10 inflammatory targets (PDK1, RAC1, PTK6, KDR/VEGFR2, EGFR, endothelin-1, caspase-3, TNF-α, NF-κB1/BTK, TLR/IRAK4) with affinities comparable to known inhibitors.
- In vivo, cilostazol reduced oxidative stress, pulmonary edema, vascular leakage, and inflammatory mediators (IL-6, TNF-α, NO, CRP, LDH, MPO, KL-6) and decreased inflammatory cell recruitment in LPS-induced ALI.
- Cilostazol downregulated mRNA expression of TNF-α, NF-κB, TLR4, and JAK/STAT3 and improved total lung capacity in rats.
Methodological Strengths
- Integrative design combining multi-target in silico docking with in vivo validation in an LPS-induced ALI rat model
- Comprehensive phenotyping including biomarkers (IL-6, TNF-α, KL-6, MPO, CRP, LDH, NO), respiratory parameters, mRNA expression, and histopathology; comparator with dexamethasone for edema
Limitations
- Preclinical single-species LPS model; human efficacy and safety unknown
- Sample size, randomization/blinding, and dose–response details not reported in the abstract; docking does not prove target engagement
Future Directions: Validate across multiple ALI/ARDS models (e.g., ventilator-induced, acid aspiration), establish dose–response and pharmacokinetics, assess bleeding risks, and progress to phase 1/2 trials to evaluate safety and preliminary efficacy.
Acute lung injury i.e. ALI and its serious form acute respiratory distress syndrome (ARDS) are incurable medical conditions associated with significant global mortality and morbidity. The objective of the present research was to repurpose cilostazol, an antiplatelet drug with anti-inflammatory, antioxidant and antiapoptotic effect, as a potential approach for treatment of ALI. Its multifaceted effects make it promising candidate but its mechanism against ALI remains elusive. Hence it is needed to elucidate its mechanism of action to revealed its therapeutic potential and improve its clinical outcomes. This study investigated the potential inflammatory therapeutic targets of cilostazol with its protective effect against lipopolysaccharide (LPS)-induced ALI. We have identified 10 inflammatory target proteins of cilostazol i.e. PDK1, RAC1, PTK6, KDR, EGFR, endothelin-I, caspase-3, TNF-α, NF-κB1/BTK, a TLR/IRAK4 by molecular docking and validated by in vivo evaluation to demonstrate its therapeutic efficacy. In vivo experiment was performed in two sets; first to determine cellular inflammation by analysing the biomarkers in both lung homogenate and bronchoalveolar fluid and second set to study lung edema with dexamethasone as a standard. Additionally, respiratory parameters, related mRNA expressions and histopathology was evaluated. Our results, molecular docking showed that cilostazol binds to identified inflammatory target proteins with the same binding affinity as that of experimental inhibitors. In vivo, downregulated oxidative stress, and inflammation i.e. attenuated the pulmonary edema and vascular leakage, release of inflammatory mediators i.e. IL-6, TNF-α, NO, C-reactive protein (CRP), lactate dehydrogenase (LDH) myeloperoxidase (MPO), Krebs von den Lungen 6 (KL-6), and the recruitment of inflammatory cells; downregulated the m-RNA gene expressions of tumour necrosis factor alpha (TNF-α), nuclear factor kappa B( NF-kB), Toll-like receptor 4 (TLR4), Janus kinase/signal transducer, and activator of transcription 3 (JAK and STAT3); and improved total lung capacity in LPS-challenged rats. These findings revealed the cilostazol's efficacy as promising therapeutic agent for ALI by inhibiting the NF-κB/TLR4/JAK-STAT3 signalling pathway.